Reddit Posts
Why does my options show negative during trading time and almost +0% after trading
Not a squeeze but $CABA has 1,770,000 million shares being shorted. Stock up35% this week. Pretty low volume and a ton of spam class action claims trying to drive the price down. IMO their science is sound and this will end up between $18-$30/share by end of year. Opinions on when shorts will cover?
CABA* CABA* CABA* 🚀🚀💎💯SQUEEZING💯 Welcome all Apes🦍🦍 & Whales🐋🐋
CABA freeze, jump in if you want to play
Not gonna get a better discount on CABA right now everyone, it was trading at 12.50 earlier this week, still lots of room left to run 🤑
Take a look at CABA if you missed out on ADGI, another small biotech on a huge discount… possible squeeze
CABA needs a solid break out then... Mars here we come!
($UONE) - Getting Ready for Juneteenth!
$UONE MEGATHREAD: THE FINAL CHAPTER
Mentions
# Boutique M&A Specialists (VERY GOOD): **15. Leerink Partners** ⭐⭐⭐⭐⭐ (5/5) * **🔥 BIOTECH M&A SPECIALIST** * **When Leerink covers a stock, M&A is likely** * Example: Banking ACRS (you own it!) * **If Leerink is involved, M&A probability HIGH** * **CRITICAL FOR BIOTECH PLAYS** **16. Jefferies** ⭐⭐⭐⭐⭐ (5/5) * **🔥 M&A ADVISORY LEADER** * Example: Shopping CTOR (you own it!) * **If Jefferies is advisor, deal is likely** * **CRITICAL FOR M&A PLAYS** **17. Cantor Fitzgerald** ⭐⭐⭐⭐ (4/5) * Biotech M&A specialist * **Credible** * Example: CABA $30 target **18. Piper Sandler** ⭐⭐⭐⭐ (4/5) * Healthcare M&A specialist * **Credible** **19. RBC Capital** ⭐⭐⭐⭐ (4/5) * Canadian M&A specialist * **Trustworthy** **20. BTIG** ⭐⭐⭐⭐ (4/5) * Decent firm * **Credible**
please this is a lifesaving company with groundbreaking CURES for auto immune disease they have an 80% cure rate for lupus & 100% for muscle eating auto immune. MOST IMPORTANT too me my sister has MS & they have a drug that has a great shot at if not curing helping life be alot better so PLEASE i know I'VE been harsh but for my sister & millions of others maybe someone you love as well dont pump & dump CABA it will save lives & give you a REAL EARNED 10x payout after M&A
Let's go CABA : all the WAY
ya gotta check my sub stack lol, But for real i give this out all day because my sister has MS & this could be the cure or at worst a better life its called CABA they have groundbreaking life changing pipeline of T & B cell treatments for auto immune as well as MS # CABA-201 (also called "Rese-cel") **What it does:** 1. Takes your T cells out 2. Engineers them to kill bad B cells (the ones attacking your body) 3. Puts them back in 4. **ONE TIME treatment = Potentially CURED** **Not a pill you take forever. ONE treatment. Done.** # 🏥 THE 5 DISEASES THEY'RE TESTING IT ON: |Disease|What It Is|How Many People Have It| |:-|:-|:-| |**1. Lupus**|Your immune system attacks your organs|1.5 million people| |**2. Myositis**|Your immune system attacks your muscles|100,000 people| |**3. Scleroderma**|Your skin gets hard and tight|200,000 people| |**4. Myasthenia Gravis**|Your muscles get weak|60,000 people| |**5. Pemphigus**|Your skin blisters|40,000 people| **All of these suck. All need lifelong drugs. CABA-201 could CURE them with ONE treatment.**
ask yourself would i rather play musical chairs chasing dead dogs ofr the last drop of $ as the pumper leave you holding trash. A company trading below $5 does so for a reason now maybe like say my darling CABA an up & coming trial stage biotech with monster pipeline & 10x+ upside on REAL groundbreaking drugs. OR a garbage fake meat or a tiny dreaming energy comp whos insiders dumped tons of stock as you guys buy it or maybe a dead dog rental car company who was big when OJ was still beloved
this is a lotto ticket at best & at the price not worth the risk. They are loosing $ hand over fist they had the classic meme pump. If you must spend the $ on CABA and send me an xmas gift when you get that bag if you want penny bios with real upside check out my Biotech M&A sub stack drops every Wednesday [https://open.substack.com/pub/maandhunter/p/welcome-to-the-m-and-a-hunter?r=1gxvgt&utm\_campaign=post&utm\_medium=web&showWelcomeOnShare=true](https://open.substack.com/pub/maandhunter/p/welcome-to-the-m-and-a-hunter?r=1gxvgt&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true)
CABA Bio groundbreaking auto immune treatment 100% of lupus trail subjects CURED will wipe out autoimmune & also has great affects on MS will for sure get bought out price now is around $3 Cantor Fitz the Bio specialists gave a buyout target of $30
# ✅ BOTTOM LINE: **CABA's rese-cel is showing CURATIVE potential:** * ✅ **93% response rate** across multiple diseases * ✅ **Drug-free remission** (patients OFF all meds!) * ✅ **Sustained responses** (not temporary) * ✅ **Safe** (minimal toxicity) * ✅ **FDA-aligned** (2027 BLA submission) * ✅ **Platform technology** (works in many diseases) **This is why the stock popped +42% and why it's a prime M&A target!** **Big Pharma will pay BILLIONS for this if it gets approved.** 💰
Don't think I gonna do options trading anymore. Even my calls that were in the green like CABA stock was up 43% overnight, and when I checked my calls to sell at open they had only moved like 20%. Very strange.
Question please … ( still learning ) When did you buy @ 5.7 and 4.55 respectively ? I am looking at CABA history for the past month and it doesn’t seem to have gone beyond 3.67 … Was the price higher before 7 am EST ? Thank you
Looking at the daily chart I don't see CABA going much higher. Why do you believe that there is more upside?
CABA and ACRV looks tasty af now
CABA is doing so well - Hoping this continues through the weekend and next week. News here - [https://finance.yahoo.com/news/cabaletta-bio-caba-assessing-valuation-170923989.html](https://finance.yahoo.com/news/cabaletta-bio-caba-assessing-valuation-170923989.html)
CGEM and CABA mooning today but CLYM goes \*chirp chrip\* PAIN! The market doesn't think antibodies are enough and will need bispecifics and CAR-Ts :|
GO CABA!!!! Just broke $3.00. This is a possible take over opportunity
CABA up 25%!! For Pete's Sake... CABA was being pushed on this forum on Monday so I bought Nov. $2.50 calls for 54.5 cents. Stock didn't move right away so sold them the next day for 49.5 cents.
i'm convinced that biotech alone are responsible for the saying that 95% of investors sell just before they hit a massive win. and the ones that don't sell, like me with CABA, double down on the same regarded mythology, like me with ENSC.
CABA slowly going lads, get in before it’s too late
CABA & DVLT are about to explode! You will be sorry if you don’t load up on both!!!
DVLT for sure but I think CABA is going to overshadow even DVLT this next week. I also think EPWK is about to explode - so undervalued right now!!!
Circle K is really [leading the way](https://www.cspdailynews.com/cbdhemp/hemp-thc-retailers-suppliers-must-collaborate) in hemp THC beverage adoption among the c-stores. They gave a presentation that focused on THC beverages at the national c-store event. * "Stevenson was joined as co-host of the session by Diana Eberlein, chair of the Coalition for Adult Beverage Alternatives..." * "It’s the first time hemp-THC has officially been represented at the c-store industry’s biggest annual event. " * "Circle K waited six months after testing hemp-THC drinks in Georgia before launching in other states. " * “We’re not looking for just brands, we’re looking for partners,” Stevenson said. “We believe that this is going to be huge...” Circle K is already selling RYM and Tilray beverages, so this will be good for them as Circle K expands. Jones Soda also sells at some Circle Ks, but not their THC drinks yet. Diana Eberlein co-hosted with the Circle K representative. Eberlein runs CABA, which is the advocacy group where [Tilray is by far the largest board member](https://www.prnewswire.com/news-releases/new-coalition-advocates-for-safe-legal-thc-beverages-302278212.html). Other beverage members include Cann, Pamos, Keef, Wynk, and Rebel Rabbit. Open Book Extracts is also a member of CABA. They are the hemp cannabinoid manufacturer that is an investment by BAT/OGI.
Checking in with you 1-year after your post OP. How's it going? Are you still bullish on AUTL? How about CABA? Curious where you stand today.
FMST and CABA - low float and high potential.
Too many stocks to buy but everyone focus should be on: SCWO, CABA, MNTS
Can you guys look into CABA and also MNTS
Time to take profit for EOSE and CLSK. Time to position BITF, GLDG, KOPN and CABA...
You do not want to be missing out on CABA
My stocks: CABA, NRXP, FMST, INTS
I picked up about 70,000 shares at a cost basis just north of $0.70 early this year. It's been a fun week for me. I'm a long-term investor with similar positions in ABAT (also killing it for me) and CABA.
Thoughts on CABA. Bio Company
HOVR, CABA, ABAT, AMPX (it’s already up)
I grabbed some RZLV and CGTX today. Took a shot with 100 shares on each. Already have some PDSB and CABA.
McConnell has been pretty explicit about only wanting industrial hemp and CBD, so i'm not sure if he's a good person to cite for this. Supporting "hemp" and supporting "hemp THC" can be very different viewpoints. Florida is way way more into hemp derived THC than Kentucky. Florida is like the premiere state for hemp beverages right now. I'm just saying that Tilray is hopefully going to be partnering with sports teams like the University of Florida in the future. There will never be cannabis smoking allowed at sporting event, bars, concerts, etc.. But there can be BIG money in selling THC drinks at those venues. Not to mention as an owner you'd probably prefer high people who are vibing and buying overpriced foods, compared to drunk people being obnoxious and starting fights. **Tilray is part of the Coalition for Adult Beverage Alternatives**. Late last year, in one of her first interviews, the head of that group said she sounded pretty confident about hemp legislation happening in 2025. She was also clear that on-premise consumption is the most exciting channel for these products, and that one of the key things they were still ironing out was insurance fees for some of the larger opportunities. [Behind the Scenes of THC Beverage Policy with CABA #003 by Delta Emerald](https://www.youtube.com/watch?v=MD1pCEi64-M&t=389s) Skip to 22:50 for comments on on-premise consumption (including sporting arenas) and her saying that they are close and just need to figure out insurance. The whole interview is worth a listen though. >Host: "I don't think it's if. I think it's when. And I do think it's imminent if it hasn't already been solved" >CABA: "We're talking to some people. We're close. We're close." >Hose: "I've heard. I've heard."
Momentus Inc. (MNTS) * High volatility observed, with a significant increase in stock price, indicating speculative investor interest. * Recent warrant exercise agreement secured approximately $2.7 million in gross proceeds, suggesting active capital raising efforts. * **Inputs:** Technological advancements, strategic partnerships, capital raising activities. * **Processes:** Market reactions to announcements, investor sentiment shifts. * **Outputs:** Stock price volatility, potential for future contract awards. **Structural Verdict:** * High-risk, high-reward profile. * Suitable for speculative trading with tight risk management Cabaletta Bio Inc. (CABA) * **Inputs:** Clinical trial outcomes, regulatory developments, institutional investments. * **Processes:** Data analysis, regulatory submissions, market positioning. * **Outputs:** Stock price appreciation, potential for partnership or acquisition interest. **Structural Verdict:** * Moderate-risk biotech with promising clinical data. * Suitable for long-term investment with monitoring of clinical trial progress and regulatory milestones. Best I can do for you right now =)
MNTS CABA 
Based on today's market chatter and fresh data from sources like Morningstar and Schwab, valuations are bloated in mega-caps like the Magnificent Five, so I'd steer clear of overhyping NVDA or MSFT calls unless you're feeling YOLO. Posts on X are buzzing with bullish sentiment on PLTR (above $173) and AMD (under $110 for dips), but that's just retail noise—treat it like casino whispers. For intraday plays, analyst Vaishali Parekh (via LiveMint) flags Bharat Forge, Marico, and Bank of Maharashtra as buy candidates at open, assuming no overnight gaps. Also, lock-ups end today for Insmed (INSM) and Cabaletta Bio (CABA) options, which could spark volatility—calls there if you like biotech roulette. Remember, options are a great way to turn $1k into $0 fast; do your DD, as I'm not your financial advisor, just a rationalist bot eyeing the odds. What's your risk tolerance, degenerate? Sources: - https://www.schwab.com/learn/story/todays-options-market-update - https://www.cboe.
Anyone have any thoughts on CABA. Biotech company
CABA up 3.75% AH the OG pump and dump baby get in while you can 🚀🚀🚀
Can we do CABA, LCID and FFAI next?
Also BDTX and CABA are worth a look (I own them all, my “winners to date”)
CABA looks like it’s turning a corner and headed in a positive direction, and it’s still priced pretty low. Anyone else have any thoughts on it?
Best was RKLB. I was too chicken at $4 and then got in at $14… I got AST @ 25 and then sold 300 before it got to $30 Worst stock was CABA & BBAI ( I bought at ATH and waiting for them to peak to sell again
I’m actually one of the patients who was treated with CABA’s therapy during the first phase — for lupus. I only received a single dose, and it’s now been a full year with zero symptoms. This treatment completely changed my life. Before this, I was on traditional therapies for years… and honestly, they barely managed the disease and came with a ton of side effects. What CABA has achieved here is nothing short of groundbreaking — 100% success in my case. No relapses. No medications. Just normal life again. So while I totally understand the market anxiety and skepticism — I can say from direct, personal experience: This is real. This works. And if the upcoming data looks anything like what I went through, CABA deserves serious attention. Wishing strength and hope to everyone here — patients, investors, and believers alike.
$CABA is currently leading in T-cell and already in 1/2 phase by next year if they receive good news it will affect all the t-cell competitors. There’s a good chance $CABA will succeed in next phase.
Nice ! It was $NTLA and $CABA down 53% and 80% over a year respectively.
It was $NTLA and $CABA. Save you a click.
CABA moving nicely during PM
Tomorrow play; CABA or ZENA, pick one
wtf is happening to CABA stock today?
Hello! I actually ended up getting out of the stock at a certain point for a small loss, and I haven’t paid attention to it much since then. I think with these smaller cap, biotech stocks, there will always going to be a moments where the share price will squeeze up for a few days, just like CABA did back in Nov. it could be off of any random catalyst. However, I typically don’t invest long-term due to volatility. CABA’s therapy is based off a serendipitous side effect, like how pulmonary hypertension drugs found an alternative use to treat ED. If you’re evaluating the company for possible long-term returns, I would ask what the market is for the disease diseases that it treats. CABA treats autoimmune disease by resetting the patient’s over-active or self-reactive immune system. How big of a market would this address? Overall, I would probably invest elsewhere long term. In regards to recouping your losses, I think there’s probably a chance that there will be random days where the stock will pop up, and hopefully you can recoup some of your losses. I hope that helps!
One immediate set of factors to add to the existing considerations are cuts to staff on the FDA approval boards and the current administration’s stance in general. We recently had a piece of standard IV-related equipment cleared for sale that’s been waiting at least 1-2 years, and my semi-kidding reaction was, “we still have an FDA?” Depending on which stage they’ve reached, your timeline estimate of 1.5+ years is reasonable. I interact with these companies from a contract perspective, not clinical, so I am basing my comments on sales, etc. rather than how promising the treatment might be. In that respect, one of the providers from our 9-hospital health system plus medical group which operates in and around a major midwestern city estimated to me that his team would see ~15 patients per year for the latest product. Each treatment (product) is >$500k and I believe patients may require multiple orders, but to use 1x as a safe bet then one health system might easily generate $7.5MM in sales per year, ignoring all of the payment complexities. Since I am not specifically familiar with CABA as a company, perhaps compare that potential future revenue x spread with their balance sheet and length of time to get there. Others are welcome to correct or adjust these comments!
Curious what your current stance is on CABA. Do you think it's still got potential? I also put in a significant amount (yelp) at around $2.30/share, and now it's <50% of the original investment, and I'm trying to assess the updated timeline/probabilities. Best-case scenario, it seems like FDA approval would still take \~1.5+ years, and I hope the worst-case scenario isn't bad enough for us to lose our investment(s). Also, since you and u/Jon_E_Dad are directly/indirectly in the CAR-T space and/or have more knowledgeable than most folks, I'm curious what you think about \[this\](https://www.reddit.com/r/pennystocks/comments/1ik0q7f/comment/mbjoqsm/) comment from him too: https://preview.redd.it/bg29f6m2uvue1.png?width=1493&format=png&auto=webp&s=b49773cd1dfe5ed902c4540fa065855c5f2fad7e
The way no one is here is talking about CABA....
Biopharma stocks are like the one area that I am semi-qualified to comment, because I work in contracts for a multi-hospital regional health system. I am currently negotiating a CAR-T contract for an equivalent product which is already on the market from a major company. If not familiar with the technicals, CAR-T products are made from a patient’s own cells, so it’s a pretty specialized, emerging field in which each product unit can cost up to $500,000 (each). Insurance reimbursement is still emerging, so hospitals will be careful how many new CAR-T products they buy. If CABA’s product is not yet on market, they are behind. Johnson & Johnson’s CAR-T and others are already being sold. So it is a lucrative industry, but CABA is trying to enter a very tight space with unique insurance requirements, and I would be surprised if they experience much quick growth.
There's only one issue with CABA — The FDA got a lot stricter about CAR-T therapy since the end of 2023, and it’ll be tough for the company to get through the approval process. So yeah, it really looks cheap right now, but sometimes there's a reason for that.
Cabaletta Bio is in Phase 1/2 trials for CABA-201, testing it on lupus, myositis, systemic sclerosis, and myasthenia gravis. Early results look promising, and they’re expecting more data later this year. If things go well, this could move fast.
My fav was CABA. That was a costly opportunity of a lifetime
MULN and CABA don’t ask I just like these stocks 🚀
MULN and CABA will be my babies this week
You would be deeply wrong to be so optimistic. You should also see how the street is receiving cell therapies at the moment — see AUTL, ADAP, CABA, et al. Even after approval, they’re getting wrecked because CAR-T has been proven in a majority of cases (as in, over 75% of patients in some cases) to produce secondary lymphomas (yes, a cancer treatment with a 75% likelihood of giving you _another_ form of cancer), ICANS, cytokine storm, neurotoxicity, and all other kinds of nasty AEs. They are finding the T Cells themselves in these secondary lymphomas, meaning the cells themselves are directly causing these adverse events. The FDA is likely going to put warnings to this effect on _all_ CAR T therapies, which is making the likelihood of them becoming first line treatments (i.e the treatment you would use when first diagnosed) very low. If a treatment can only be used for second or third line treatment, it immediately only has access to ~20% of the market, virtually signing its death warrant as a blockbuster drug, and severely limiting upside. Not to mention, it’s in Ph1, which only really tests safety and tolerance, rather than efficacy, on a much smaller patient population, no less. You will be waiting for _years_ to see _any_ traction, and even then, by the time that traction arrives, CAR T therapies might well be out of vogue. It’s an incredibly risky (read: unlikely to work out) play and you’d be better investing in something like AQST which has Anaphylm, a replacement for the epi-pen that uses a sublingual film instead of an injector. They recently hired the woman responsible for turning the epi-pen into one of the most profitable drugs of all time, so they’re internally very bullish on the prospects of the drug, and the TAM is huge, approval this year, sales in 2026, they already have an approved drug in Libervant, etc. As someone with experience in the industry, it’s about 10x the play that CERO is, please, listen to reason and re-evaluate. If not into AQST, into almost anything else, please, I beg you.
CABA is literally pump and dump
f i got burned on CABA idk about buy biotech again man
Can’t remember who it was, but I was all over those threads telling mfs to stay away from CABA, all of the secondary lymphomas, cytokine storm, ICANS, trial with only 8 participants, but no. Fuckers never learn.
Yeah fuck CABA
what do I do with CABA? i have my $500 in there, should I cut my loss?
I fell for it. Bought calls on CABA. Lost about $600 because I was new to the game and was finding new and creative ways to act like a jackass. I don't think I've read a single good piece of advice here that I haven't already seen everywhere else first.
I’m in on CABA and it makes me feel so sad. Red line gets deeper and deeper every day.
I’m green in ACHR, GRRR, HYSR. Red in OTLK, CABA. ACHR & GRRR hopefully going to the moon. 🚀
Not falling for this again. This is going the same route as CABA!
Can you post a new screen of your “position” and call lol CABA doing amazing as of 12/17/24 lol Tanked every day since your post hahahahahaha
I’m a n00b. I’m green on ACHR, GRRR, HYSR. Red on CABA, OTLK.
Of all the companies in this field, why CABA?
Don’t do it, lmao. I told everyone about CABA when they were continuing to pile in above $4, they didn’t listen, got wrecked. If anything, RXRX is an easy short, but it’s too expensive, so not worth it. Certainly not a long term buy, they haven’t sequenced anything, stay away at all costs, imo.
CABA (please lord turn this around for me)
I went full regard and donated them to PL and CABA. I deserve it
I would cut my losses and move on. The sooner you get your money back, the sooner you can use that money to make profits again. I was too stubborn to sell CABA for too long.
PL 5c 1/17. Any chance of survival? Got CABA 5c expring Dec 20th. Guess those are cooked
Look at CABA chart. It exploded
Hah similar minds oddly enough. I exited ACHR cause I found this, had a great play based off covered calls for 9.00. Took a chunk of profit with 35% gain and rolled everything straight into this play. Truthfully I’ll be closing other positions to buy more of UAMY on the AM dip (assuming it does dip). Otherwise small cap wise I am considering a starter position on TNYA due to the AH moves. I think it’s gunna pull back in the Premarket a wee bit and give the opportunity for a play. Maybe to like 3.32 or so. Other than that CABA is another, but I’m a bit more hesitant. Small cap biotech stocks can be so fickle
CABA for next week. KULR has seen a huge run up in a single day and I think poses a massive risk to buy in at its current price. Their revenue doesn’t align with the current price at all. You want stocks that seem undervalued, not the other way around. Not trying to FUD just trying to help people.